Completed PHASE3 INTERVENTIONAL 2-arm NCT00417911

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)

Sponsor: Janssen-Cilag Ltd.

Conditions Multiple Myeloma

Interventions bortezomib

Updated 6 times since 2017 Last updated: Jun 17, 2010 Started: Dec 31, 2005 Primary completion: May 31, 2009 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00417911, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Janssen-Cilag Ltd., it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen-Cilag Ltd.
Nordic Myeloma Study Group

Data source: Nordic Myeloma Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Bergen, Norway , Herlev, Denmark , Huddinge, Sweden , København Ø, Denmark , Linköping, Sweden , Lund, Sweden , Malmo, Sweden , Odense C, Denmark , Oslo, Norway and 9 more locations